Thrombolytic Allergy: Anti-Streptokinase IgE and Alteplase Orolingual Angioedema

Streptokinase is a bacterial protein from Streptococcus pyogenes — not a human protein — and approximately 25% of adults carry pre-existing IgE antibodies to streptokinase from prior streptococcal pharyngitis or skin infections. When streptokinase is infused, these pre-existing IgE antibodies trigger immediate mast cell and basophil degranulation, producing anaphylaxis in 0.1–0.5% of treated patients. Alteplase, by contrast, is recombinant human tissue plasminogen activator — structurally identical to an endogenous human enzyme — and carries essentially no pre-existing IgE sensitization risk. Alteplase anaphylaxis rate is less than 1% and is primarily from infusion reactions rather than IgE-mediated allergy. This fundamental difference — bacterial antigen vs. recombinant human protein — explains the anaphylaxis gap between streptokinase and modern thrombolytics.

Alteplase (tPA) orolingual angioedema is a distinctive complication affecting 1.3–5.1% of acute ischemic stroke patients receiving alteplase who are also taking ACE inhibitors. The mechanism is bradykinin accumulation: alteplase generates plasmin, which cleaves kininogen to release bradykinin. ACE inhibitors block angiotensin-converting enzyme — also known as kininase II — which is the primary enzyme for bradykinin degradation. Without functional kininase II, bradykinin accumulates and causes vasogenic edema in the tongue and oropharynx. The result is rapid, potentially airway-compromising swelling that often begins unilaterally in the tongue during or shortly after the tPA infusion. This is a pharmacodynamic drug interaction, not allergy, and it cannot be predicted by standard allergy testing.

No — streptokinase should never be used again after documented anaphylaxis. After streptokinase exposure, anti-streptokinase IgE antibody titers rise 100 to 1,000-fold within 5 days and remain elevated for years. Re-exposure would trigger a more severe and potentially fatal anaphylaxis. More importantly, there is no clinical need to rechallenge with streptokinase when alteplase, tenecteplase, and reteplase are all therapeutically superior alternatives with dramatically lower anaphylaxis risk. These alternative thrombolytics do not share streptokinase's bacterial antigen structure and can be used safely after streptokinase anaphylaxis. The permanent streptokinase contraindication must be documented clearly in the patient's medical record and communicated to future treating physicians.

Management of alteplase orolingual angioedema starts with stopping the alteplase infusion if still running, then securing the airway — the highest priority given the risk of rapid progression to complete obstruction. Standard antihistamines and corticosteroids have limited efficacy because the mechanism is bradykinin-mediated rather than histamine-mediated. Icatibant, a selective bradykinin B2 receptor antagonist used for hereditary angioedema attacks, has been used off-label in several case series with apparent benefit. C1-inhibitor concentrate, which accelerates bradykinin breakdown by restoring kinin-degrading enzyme activity, is another off-label option. Early anesthesia or ear-nose-throat consultation for awake fiberoptic intubation is recommended when tongue swelling is progressive — cricothyrotomy is a rescue option for complete obstruction. Most patients recover fully after drug cessation and appropriate airway management.

Alteplase (Activase), tenecteplase (TNKase), and reteplase (Retavase) are the primary modern streptokinase alternatives. Alteplase is the FDA-approved agent for acute ischemic stroke, massive PE, and acute MI (as a 90-minute weight-based infusion). Tenecteplase is a single-bolus engineered tPA variant with longer half-life and greater fibrin specificity, preferred in many acute MI protocols for its operational simplicity, and is increasingly studied for acute stroke. Reteplase is a double-bolus modified tPA used in acute MI. All three agents are recombinant human proteins with low immunogenicity and anaphylaxis rates well below streptokinase. Urokinase (Kinlytic) — derived originally from human urine — remains available for catheter-directed thrombolysis in peripheral vascular disease and PE. None of these agents share streptokinase's bacterial streptococcal antigen.

Yes — prior streptococcal pharyngitis or skin infection raises anti-streptokinase IgE antibody levels, which is exactly why approximately 25% of adults carry baseline anti-streptokinase IgE. Recent strep infection, within the past few months, may produce transiently elevated antibody titers that heighten acute anaphylaxis risk more than the baseline population level. However, clinically acute streptokinase administration cannot be deferred to allow antibody titer decline in emergencies — the decision must weigh the thrombolytic benefit against anaphylaxis risk. In clinical practice, the near-universal availability of alteplase in acute MI, PE, and stroke settings in developed countries makes this distinction largely moot. In resource-limited settings where streptokinase may be the only available fibrinolytic, the 0.1–0.5% anaphylaxis risk is accepted given the mortality benefit of thrombolysis in acute MI.

No — bleeding is the predictable, mechanism-based pharmacologic effect of thrombolytics and is entirely different from allergy. Thrombolytics dissolve fibrin clots by activating plasmin — this same mechanism non-selectively dissolves hemostatic clots at bleeding sites. Intracranial hemorrhage risk from alteplase in acute stroke is approximately 0.4–6% depending on patient age, infarct size, and blood pressure control. This is a pharmacologic risk, not an immune reaction, and it is not predicted by allergy history, skin testing, or IgE levels. Patients labeled as having thrombolytic allergy when their actual concern was bleeding complications may be unnecessarily denied life-saving thrombolysis in future emergencies. True thrombolytic allergy — IgE-mediated anaphylaxis from streptokinase or infusion reactions — is separate from and should not be conflated with the bleeding risk inherent to all fibrinolytic therapy.

The decision to switch ACE inhibitor to ARB specifically to reduce orolingual angioedema risk with potential future tPA use requires individual cardiovascular risk-benefit analysis. ARBs (losartan, irbesartan, valsartan, candesartan, olmesartan) do not inhibit ACE/kininase II and therefore do not potentiate bradykinin accumulation — they carry substantially lower orolingual angioedema risk than ACE inhibitors both independently and when combined with thrombolytics. For most cardiovascular indications — hypertension, heart failure, post-MI, CKD with proteinuria — ARBs have equivalent outcome data to ACE inhibitors and represent a clinically reasonable alternative. Some practitioners routinely prefer ARBs in high-stroke-risk patients who may need tPA in the future. The acute setting of stroke presenting while on ACE inhibitor does not allow for medication switching — the ACE inhibitor history must simply be factored into airway monitoring intensity during and after tPA infusion.

Streptokinase is a bacterial protein from Streptococcus pyogenes with abundant pre-formed IgE antibodies in approximately 25% of adults — making IgE-mediated anaphylaxis a well-characterized class risk. Tenecteplase is an engineered recombinant human tPA variant — structurally a modified human protein — with no bacterial antigen component. Pre-existing IgE sensitization to tenecteplase is exceptionally rare because the human immune system does not typically form IgE against endogenous human protein structures. Tenecteplase infusion reactions, when they occur, are typically non-IgE-mediated infusion reactions (cytokine release, complement activation) rather than classic anaphylaxis. The practical consequence is that streptokinase anaphylaxis requires immediate permanent streptokinase avoidance and clear documentation, while tenecteplase reactions are typically managed with slower infusion rates or premedication rather than permanent contraindication.